1 Min Read
Feb 22 (Reuters) - Helix Biopharma Corp:
* HELIX BIOPHARMA - BOARD AUTHORIZED PROCESS TO EXPLORE PARTNERSHIP, JOINT DEVELOPMENT OR LICENSING TRANSACTION OF CO’S L-DOS47 DRUG PRODUCT CANDIDATE Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.